Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: A double blind comparative study with ondansetron tablets

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 323-326

  De Wit, R ^a   Beijnen, J H ^b   Van Tellingen, O ^c   Schellens, J H M ^a   De Boer Dennert, M ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

5HT3 receptor antagonist; Antiemetic

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; ONDANSETRON;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; SUPPOSITORY; TABLET; VOMITING;

EID: 0030016203     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.361     Document Type: Article

References (9)

1. BONNETERRE J, CHEVALLIER B, METZ R, FARGEOT P, PUJADE-LAURAINE E, SPIELMAN M, TUBIANA-HULIN M, PAES D AND BONS J. (1990). A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J. Clin. Oncol., 8, 1063-1069.
2. COATES A, ABRAHAM S, KAYE SB, SOWERBUTTS T, FREWIN C, FOX RM AND TATTERSALL HN. (1983). On the receiving end patients perception of the side effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol., 19, 203-208.
3. COLTHUP PV, FELGATE CC, PALMER JL AND SCULLY NL. (1991). Determination of ondansetron in plasma and its pharmacokinetics in young and elderly. J. Pharm. Sci., 80, 868-871.
4. CUPPISOL D, BRESSOLLE F, ADENIS L, CARMICHAEL J, BESSELL E, ALLEN A, WARGENAU M AND ROMAIN D. (1993). Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J. Pharm. Sci., 82, 1281-1284.
5. HSYU PH, PRITCHARD JF, BOZIGIAN HP, GOODING AE, GRIFFIN RH, MITCHELL R, BJURSTROM T, PANELLA TL, HUANG AT AND HANSSEN LA. (1994). Oral ondansetron pharmacokinetics: the effect of chemotherapy. J. Clin. Pharmacol., 34, 767-773.
6. KAASA S, KVALOY T, DICAT MA, RIES F, HUYS JV, ROYER E AND CARRUTHERS L. (1990). A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur. J. Cancer, 26, 311-314.
7. MARSCHNER NW, ADLER M, NAGEL GA, CHRISTMANN D, FENZL EAND UPADHYAYA B. (1991). Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur. J. Cancer, 27, 1137-1140.
8. PRITCHARD JF. (1992). Ondansetron metabolism and pharmacokinetics. Semin. Oncol. 19, 9-15.
9. SHAH VP, MIDHA KK, DIGHE S, MCGILVERY J, SHELLY JP, YACOBI A, LAYLOFF T, VISWANATHAN CT, COOK CE, MCDOWALL RD, PITTMAN KA AND SPECTOR S. (1992). Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J. Pharm. Sci., 81, 309-312.